Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Effectiveness · EFFECT

Lycia Therapeutics, Inc.

LYCANASDAQEQUITYCurrent

Notice of Effectiveness

Filed Oct 22, 2026Accepted Oct 23, 2026, 12:15 AM EDTFiling CIK 1806540Accession 9999999995-26-003321
Share

Structured filing — EFFECT

primary_doc.xml

Open full document ↗

Notice details

Submission type
EFFECT
Act
33

Effectiveness

Effective date
2026-10-22
Effective time (as filed)
16:00:00
Form
S-1

Registrant 1

Registrant
Lycia Therapeutics, Inc.
Registrant CIK
0001806540
File number
333-299300

Company context

We are a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases. By leveraging our proprietary LYTAC (Lysosomal Targeting Chimera) platform, we have developed a pipeline of therapeutic candidates with the potential to provide deep and durable elimination of extracellular proteins that are inadequately addressed by currently available therapies. We are seeking to advance these therapeutic candidates through a streamlined clinical development strategy designed to generate early proof of concept, including Phase 1 pharmacodynamic and biomarker data, to assess target modulation and inform progression into later-stage clinical development. Our immunoglobulin E (IgE) portfolio consists of LCA-0061 and LCA-0062, which are both designed with an aim to efficiently degrade IgE for the treatment of allergic diseases, including food allergy. We are conducting a Phase 1 clinical trial of LCA-0061 in participants with elevated IgE, including patients with food allergy. Preliminary data from our first cohort of healthy atopic participants treated with a single 70 mg subcutaneous (SC) dose of LCA-0061 showed rapid, deep and sustained reduction in total and free IgE. We believe the initial LCA-0061 clinical data supports a differentiated profile from IgE blockers and provides initial human proof-of-mechanism

Current securities

Recent company filings

  1. SCHEDULE 13G - filed by Venrock Healthcare Capital Partners III, L.P. regarding Lycia Therapeutics, Inc.Oct 30, 2026
  2. 4 filingOct 26, 2026
  3. 4 filingOct 26, 2026
  4. 4 filingOct 26, 2026
  5. 4 filingOct 26, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.